Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure

By sjmartinez • December 24, 2022

Talha KM, Fonarow GC, Virani SS, Butler J. Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. Methodist Debakey Cardiovasc J. 2022 Dec 6;18(5):40-53. doi: 10.14797/mdcvj.1155. PMID: 36561085; PMCID: PMC9733124.

Tags: Cardiology/Epi, cardiovascular disease, glucagon-like peptide 1 receptor agonist, heart failure, prevention, Publications, sodium-glucose cotransporter-2 inhibitor

Related Posts

Intensive Versus Standard Blood Pressure Control After Endovascular Thrombectomy in Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials

Hashmi TM, Ahmed M, Ashraf H, Shakir M, Bhatti IA, Ahmed F, Alareed A, Hasan A, Ahmed R, Rafiq S, Aized MT, Fonarow GC, Hassan[...]

p21+TREM2+ senescent macrophages fuel inflammaging and metabolic dysfunction-associated steatotic liver disease

Salladay-Perez IA, Avila I, Estrada L, Alexandru AC, Ponce C, Dhingra A, Torres G, Deng CY, Hegde R, Gensheimer J, Kale A, Heckenbach I, Hui[...]

InChagas: Feasibility Study of a Tele-Education Strategy to Promote Early Identification and Care of People Living with Chagas Cardiomyopathy in an Endemic Community in Argentina

Gulayin PE, Gimenez C, Chirino D, Nascimento B, Salvá L, Cavallo AS, Gutierrez L, Blanco L, Flores LPC, Espina E, Shakil SS, Vervoort D, Davis[...]